The significance of plasmid DNA preparations contaminated with bacterial genomic DNA on inflammatory responses following delivery of lipoplexes to the murine lung

Biomaterials

Volumn 32, Issue 36, 2011, Pages 9854-9865

  Bazzani, Reto P ^a,c   Cai, Ying ^b   Hebel, Henry L ^b   Hyde, Stephen C ^a,c   Gill, Deborah R ^a,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b VGXI Inc   (United States)

^c United Kingdom Cystic Fibrosis Gene Therapy Consortium   (United Kingdom)

Author keywords

Bacterial genomic DNA; Cytokine; Gene therapy; Lipoplex; Lung inflammation; Plasmid

Indexed keywords

CYTOKINES; GENOMIC DNA; LIPOPLEXES; LUNG INFLAMMATION; PLASMID;

BACTERIOLOGY; BIOLOGICAL ORGANS; BIOMOLECULES; CONTAMINATION; GENE THERAPY; GENE TRANSFER; LIPOSOMES; MANUFACTURE; PATHOLOGY;

DNA;

BACTERIAL DNA; CYTOKINE; DINUCLEOTIDE; GENOMIC DNA; LIPOPLEX; PLASMID DNA;

ARTICLE; BACTERIUM CONTAMINATION; CHEMICAL MODIFICATION; CYTOKINE RELEASE; DNA METHYLATION; DNA SEQUENCE; FEMALE; INFLAMMATION; LUNG LAVAGE; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PRIORITY JOURNAL;

ANIMALS; BIOLOGICAL MARKERS; BRONCHOALVEOLAR LAVAGE FLUID; CPG ISLANDS; CYTOKINES; DNA CONTAMINATION; DNA, BACTERIAL; DRUG DELIVERY SYSTEMS; ELECTROPHORESIS, AGAR GEL; FEMALE; GENOME, BACTERIAL; HUMANS; INFLAMMATION; LIPOSOMES; LUNG; MICE; MICE, INBRED BALB C; PLASMIDS; TOLL-LIKE RECEPTOR 9;

BACTERIA (MICROORGANISMS); MURINAE;

EID: 80054070494     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2011.08.092     Document Type: Article

References (40)

1. Gao X., Kim K.S., Liu D. Nonviral gene delivery: what we know and what is next. AAPS J 2007, 9:E92-E104.
2. Griesenbach U., Alton E.W. Current status and future directions of gene and cell therapy for cystic fibrosis. BioDrugs 2011, 25:77-88.
3. Welsh M.J., Ramsey B.W., Accurso F., Cutting G.R. Cystic fibrosis. The Metabolic and Molecular Bases of Inherited Diseases 2001, 5121-5188. McGraw-Hill, New York. 8th ed. C.R. Scriver, A.L. Beaudet, W.S. Sly, D. Valle (Eds.).
4. Alton E.W., Stern M., Farley R., Jaffe A., Chadwick S.L., Phillips J., et al. Cationic lipid-mediated CFTR gene transfer to the lungs and nose of patients with cystic fibrosis: a double-blind placebo-controlled trial. Lancet 1999, 353:947-954.
5. Ruiz F.E., Clancy J.P., Perricone M.A., Bebok Z., Hong J.S., Cheng S.H., et al. A clinical inflammatory syndrome attributable to aerosolized lipid-DNA administration in cystic fibrosis. Hum Gene Ther 2001, 12:751-761.
6. Freimark B.D., Blezinger H.P., Florack V.J., Nordstrom J.L., Long S.D., Deshpande D.S., et al. Cationic lipids enhance cytokine and cell influx levels in the lung following administration of plasmid: cationic lipid complexes. J Immunol 1998, 160:4580-4586.
7. Li S., Wu S.P., Whitmore M., Loeffert E.J., Wang L., Watkins S.C., et al. Effect of immune response on gene transfer to the lung via systemic administration of cationic lipidic vectors. Am J Physiol 1999, 276:L796-L804.
8. Norman J., Denham W., Denham D., Yang J., Carter G., Abouhamze A., et al. Liposome-mediated, nonviral gene transfer induces a systemic inflammatory response which can exacerbate pre-existing inflammation. Gene Ther 2000, 7:1425-1430.
9. Scheule R.K., St George J.A., Bagley R.G., Marshall J., Kaplan J.M., Akita G.Y., et al. Basis of pulmonary toxicity associated with cationic lipid-mediated gene transfer to the mammalian lung. Hum Gene Ther 1997, 8:689-707.
10. Hyde S.C., Pringle I.A., Abdullah S., Lawton A.E., Davies L.A., Varathalingam A., et al. CpG-free plasmids confer reduced inflammation and sustained pulmonary gene expression. Nat Biotechnol 2008, 26:549-551.
11. Yew N.S., Zhao H., Wu I.H., Song A., Tousignant J.D., Przybylska M., et al. Reduced inflammatory response to plasmid DNA vectors by elimination and inhibition of immunostimulatory CpG motifs. Mol Ther 2000, 1:255-262.
12. Hemmi H., Takeuchi O., Kawai T., Kaisho T., Sato S., Sanjo H., et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000, 408:740-745.
13. Abdullah S. Studies on the persistence of transgene expression in the murine airways 2005, University of Oxford, Oxford.
14. Yew N.S., Wang K.X., Przybylska M., Bagley R.G., Stedman M., Marshall J., et al. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum Gene Ther 1999, 10:223-234.
15. UKCFGTC. The UK Cystic Fibrosis Gene Therapy Consortium - http://www.cfgenetherapy.org.uk/clinical.html.
16. Zabner J., Cheng S.H., Meeker D., Launspach J., Balfour R., Perricone M.A., et al. Comparison of DNA-lipid complexes and DNA alone for gene transfer to cystic fibrosis airway epithelia in vivo. J Clin Invest 1997, 100:1529-1537.
17. Caplen N.J., Alton E.W., Middleton P.G., Dorin J.R., Stevenson B.J., Gao X., et al. Liposome-mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Nat Med 1995, 1:39-46.
18. Gill D.R., Southern K.W., Mofford K.A., Seddon T., Huang L., Sorgi F., et al. A placebo-controlled study of liposome-mediated gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997, 4:199-209.
19. Porteous D.J., Dorin J.R., McLachlan G., Davidson-Smith H., Davidson H., Stevenson B.J., et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther 1997, 4:210-218.
20. Hyde S.C., Southern K.W., Gileadi U., Fitzjohn E.M., Mofford K.A., Waddell B.E., et al. Repeat administration of DNA/liposomes to the nasal epithelium of patients with cystic fibrosis. Gene Ther 2000, 7:1156-1165.
21. Pringle I.A., Raman S., Sharp W.W., Cheng S.H., Hyde S.C., Gill D.R. Detection of plasmid DNA vectors following gene transfer to the murine airways. Gene Ther 2005, 12:1206-1214.
22. Gill D.R., Smyth S.E., Goddard C.A., Pringle I.A., Higgins C.F., Colledge W.H., et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor 1alpha promoter. Gene Ther 2001, 8:1539-1546.
23. Poulsen T.T., Pedersen N., Juel H., Poulsen H.S. A chimeric fusion of the hASH1 and EZH2 promoters mediates high and specific reporter and suicide gene expression and cytotoxicity in small cell lung cancer cells. Cancer Gene Ther 2008, 15:563-575.
24. Pringle I.A., McLachlan G., Collie D.D., Sumner-Jones S.G., Lawton A.E., Tennant P., et al. Electroporation enhances reporter gene expression following delivery of naked plasmid DNA to the lung. J Gene Med 2007, 9:369-380.
25. Guidance for industry: consideration of plasmid DNA vaccines for infectious disease indications 2007, FDA. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091968pdf.
26. Note for guidance on the quality, preclinical and clinical aspects of gene trasnfer medicinal products 2001, EMEA.
27. Cai Y., Rodriguez S., Hebel H. DNA vaccine manufacture: scale and quality. Expert Rev Vaccines 2009, 8:1277-1291.
28. Lee E.R., Marshall J., Siegel C.S., Jiang C., Yew N.S., Nichols M.R., et al. Detailed analysis of structures and formulations of cationic lipids for efficient gene transfer to the lung. Hum Gene Ther 1996, 7:1701-1717.
29. Hebel H., Attra H., Khan A., Draghia-Akli R. Successful parallel development and integration of a plasmid-based biologic, container/closure system and electrokinetic delivery device. Vaccine 2006, 24:4607-4614.
30. Emerson M., Renwick L., Tate S., Rhind S., Milne E., Painter H.A., et al. Transfection efficiency and toxicity following delivery of naked plasmid DNA and cationic lipid-DNA complexes to ovine lung segments. Mol Ther 2003, 8:646-653.
31. Mantovani A., Sica A., Sozzani S., Allavena P., Vecchi A., Locati M. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004, 25:677-686.
32. Krieg A.M. CpG motifs in bacterial DNA and their immune effects. Annu Rev Immunol 2002, 20:709-760.
33. Zhao H., Wu I.-H., Hemmi H., Akira S., Cheng S.H., Scheule R.K., et al. Role of the toll-like 9 receptor in the acute inflammatory response to nonviral vectors. Mol Ther 2003, 7:S209.
34. Wooddell C.I., Subbotin V.M., Sebestyen M.G., Griffin J.B., Zhang G., Schleef M., et al. Muscle damage after delivery of naked plasmid DNA into skeletal muscles is batch dependent. Hum Gene Ther 2011, 22:225-235.
35. Cai Y., Rodriguez S., Rameswaran R., Draghia-Akli R., Juba R.J., Hebel H. Production of pharmaceutical-grade plasmids at high concentration and high supercoiled percentage. Vaccine 2010, 28:2046-2052.
36. Wu F., Levchenko I., Filutowicz M. A DNA segment conferring stable maintenance on R6K gamma-origin core replicons. J Bacteriol 1995, 177:6338-6345.
37. Muruve D.A., Petrilli V., Zaiss A.K., White L.R., Clark S.A., Ross P.J., et al. The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response. Nature 2008, 452:103-107.
38. Takaoka A., Wang Z., Choi M.K., Yanai H., Negishi H., Ban T., et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 2007, 448:501-505.
39. Hagele H., Allam R., Pawar R.D., Reichel C.A., Krombach F., Anders H.J. Double-stranded DNA activates glomerular endothelial cells and enhances albumin permeability via a toll-like receptor-independent cytosolic DNA recognition pathway. Am J Pathol 2009, 175:1896-1904.
40. Takaoka A., Taniguchi T. Cytosolic DNA recognition for triggering innate immune responses. Adv Drug Deliv Rev 2008, 60:847-857.